Eight current targets were reviewed from sources identifying the analyst, firm, target and date. The range is extremely wide — roughly $2.79 at the low end to $13 at the high end — and the arithmetic mean of the eight is about $6.22, which rounds to the central target of $6.20. Bullish names cluster at the top: Jefferies reiterated a Buy with a $13 target in late October 2026, and Roth MKM held a $10 Buy. Cautious voices sit near the bottom: Haywood cut to $2.79, while Canaccord Genuity and Alliance Global Partners each stand at $4 with Hold ratings. In between, ATB Cormark sits at $5 and TD Cowen at $4.50. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Notably, most revisions have been downward this year — Alliance Global and Canaccord trimmed, Bernstein lowered its target from $10 to $6.50 — even as Roth Capital upgraded the stock to Buy earlier in 2026. The spread between $2.79 and $13 signals that analysts are not debating whether the business is challenged, but how much of the diversification story will ultimately translate into value.
The stock closed near $1.89 in mid-November 2026, within pennies of its $1.87 52-week low and about 88% below its $15.70 52-week high, with a market capitalization of roughly $279 million. To reach $6.20, the shares would need to appreciate about 228% — a very large move that would likely require a fundamental re-rating, not just a relief rally.
The path toward that level runs through demonstrated profitability. Tilray reported record fiscal 2026 revenue of $915 million (up 11%) and adjusted EBITDA of $61 million, and raised its fiscal 2027 adjusted EBITDA guidance to $70 million to $75 million. First-quarter fiscal 2027 revenue reached a record $257 million, driven by an 82% jump in beverage sales after the BrewDog acquisition, even as cannabis net revenue fell 13%. Investors will need to see these trends convert into sustained positive earnings before a multiple of the current share price becomes credible.
The most concrete supports are operational. BrewDog, acquired for about $54 million, has returned to profitability and now anchors a beverage segment that is Tilray's largest revenue source. International medical cannabis is growing quickly — European, Middle East and Africa revenue rose roughly 71% in the latest quarter — with the company holding a strong position in Germany's medical market. Management is also consolidating Canadian facilities for roughly $30 million in annualized savings, reduced debt to a net cash position, and ended fiscal 2026 with about $235 million in cash and marketable securities. Renewed U.S. rescheduling headlines periodically spark sharp sector rallies, though Tilray itself has no reported U.S. cannabis revenue.
The headwinds are substantial. Tilray remains unprofitable on a net basis, posted a roughly $40 million quarterly net loss, and generated negative free cash flow of about $27 million in its latest quarter. Canadian adult-use cannabis sales continue to decline under intense price competition, and adjusted EBITDA actually fell year over year in the first quarter. The company has also relied on at-the-market share offerings, which shareholders flagged as a dilution concern. Finally, U.S. federal cannabis reform remains delayed and would principally benefit U.S. operators rather than a Canadian producer, meaning the stock's historic catalyst may not materialize as hoped.
Technically, the picture is weak. The stock trades in a clear downtrend, below its 20-day and 60-day moving averages, and sits essentially at its 52-week low of $1.87 — a critical support zone alongside the round $2.00 level. Overhead, prior breakdown areas near $2.50 to $3.00 act as resistance, followed by the higher $4.00 to $5.00 band where several analyst targets cluster. A sustained move above the low-$2 range would be an early sign of stabilization, while a loss of $1.87 would mark fresh multi-year lows.
Analyst price targets typically reflect a roughly 12-month horizon, and the eight targets here span several months of activity, with most dated from early October 2026 onward. Key items to watch include the next earnings report, progress on adjusted EBITDA toward the $70 million to $75 million fiscal 2027 guidance, free-cash-flow generation, Canadian cannabis stabilization, European medical growth, and any concrete movement on U.S. rescheduling. Dilution from share issuance and integration of the beverage portfolio also warrant close attention.
For traders who prefer a data-driven complement to fundamental research, I turned to Tickeron’s AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell or Hold signals from shifting market conditions, technical behavior and AI-driven analysis. It helps surface opportunities, monitor existing positions and detect changing trends more efficiently. For a volatile name like TLRY, it offers a structured way to follow momentum and turning points alongside the analyst views.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TLRY saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 73 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric